The Liver Meeting 2020: Hepatitis Sessions

The Liver Meeting 2020: Hepatitis Sessions

AASLD 2020

The Annual Liver Meeting is here!

Below is a schedule of some of the main hepatitis events. Presentations by Coalition staff and partners are highlighted.

Friday, Nov 13th 2-3:30 pm ET |Paving the Road to Hepatitis C Elimination | Hepatitis C SIG

Objectives:

  • Review emerging strategies for U.S. and global HCV microelimination through adoption of universal screening and novel paradigms for care delivery.
  • Discuss emerging evidence and approaches to treatment as prevention for HCV in persons who inject drugs (PWID.)
  • Discuss updates in the development of an effective HCV vaccine.

Presentations:

  • Universal HCV Screening: CDC/WHO/USPSTF Recommendations, Dr. John W. Ward, Coalition for Global Hepatitis Elimination, Task Force for Global Health*
  • Novel Paradigms for Care Delivery: Treatment of HCV Beyond the Specialty Clinic, Dr. Norah Terrault, MD, MPH, FAASLD, University of California
  • Global Strategies for HCV Microelimination, Dr. Jordan J. Feld, MD, MPH, FAASLD, Toronto, University Health Network
  • Treatment As Prevention: Addressing HCV in Persons Who Inject Drugs (PWID), Dr. Stacey Trooskin, Philadelphia Fight
  • Future of HCV Vaccine Development, Dr. Andrea Cox, Johns Hopkins Hospital
  • Use of HCV Positive Organs in Transplantation, Dr. David S Goldberg, University of Miami School of Medicine

Saturday, Nov 14th 10:30-11:30 am ET | Global Symposium

Objectives:

  • Review unmet needs in HCV diagnosis and treatment approaches specific to various world regions.
  • Discuss new advances in HCV testing and treatment from Africa. Europe, North and South America and Asia-Pacific regions, and how to apply successful approaches in other regions.
  • Discuss existing challenges and barriers to achieving a realistic test-and-cure approach to eliminate HCV worldwide.

Program Chairs

  • Michael W. Fried, Target Pharmasolutions, Inc., Durham, NC
  • Stacey Trooskin, Philadelphia Fight

Presentations

  • Welcome and Introductions, Dr. Stacey Trooskin, Viral Hepatitis, Philadelphia Fight
  • Viral Hepatitis Elimination in Africa, Olufunmilayo Lesi, University of Lagos
  • Viral Hepatitis Elimination in Central and South America, Dr. Marcello O. Silva, Hepatology and Liver Transplant Unit, Hospital Universitario Austral
  • Viral Hepatitis Elimination in Europe, Maria Buti , Liver Unit, Internal Medicine Department. Hospital Universitari Vall d’Hebron, Barcelona, Spain, University Hospital Vall D'hebron
  • Viral Hepatitis Elimination in North AmericaDr. Andrew I. Aronsohn, Center for Liver Diseases, The University of Chicago Medicine

Saturday, Nov 14th 12-1:00 pm ET |Paving the Road to Hepatitis C Elimination Break-Out Sessions

Saturday, Nov 14th 5:30-7:00 pm ET |Parallel Session: Hepatitis C: Epidemiology

  • Determining Feasibility of Hepatitis C Elimination in the United States Using a Simulation Model, Presenting Author Madeline Adee
  • Circulating microRNAs Profiles to Predict the Risk of HCC Development in DAA-Treated HCV-Related Cirrhosis, Presenting Author Massimo Levero
  • Can Hepatitis C Treatment with Direct-Acting Antivirals be Cost Saving? A Global Modeling Study of 158 Countries, ‍Presenting Author Madeline Adee
  • HCC Risk Post-SVR with DAAS in East Asians: Findings from the Real-C Cohort, Presenting Author Yasuhito Tanaka
  • Low Adherence to Infant HCV Testing Guidelines Among Pregnant Women with HCV Cirrhosis, Presenting Author Tatyana Kushner
  • Country and WHO Regional Trends for Hepatitis C Virus (HCV) Mortality, 1990-2019: An Analysis of the Global Burden of Disease (GBD) Study
    Presenting Author Abigail Adams * CGHE Author

Saturday, Nov 14th 9-10:00 pm Rebroadcast: Global Symposium - Global Elimination of Hepatitis C: From Ideas to Action

Sunday Nov 15th 2-3:30 pm ET | COVID-19 and the Liver Symposia

Objectives:

  • Identify ways in which COVID-19 clinically manifests in patients with liver disease and cirrhosis
  • Compare the treatments for COVID-19
  • List available vaccine strategies to prevent COVID-19

Presentations:

  • Welcome and Introductions, Dr. Robert J. Fontana, MD, FAASLD, Division of Gastroenterology and Hepatology, University of Michigan
  • COVID-19 Overview and Vaccine Summary, Anthony S Fauci, National Institute of Allergy and Infectious Diseases
  • Hepatic Manifestations of COVID, Dr. Elizabeth C. Verna, MD, MS, Liver Diseases and Transplantation, Columbia University Medical Center
  • Current Therapy of COVID-19 & Hepatic Issues Related to Therapy, Mark S. Sulkowski, Johns Hopkins University
  • Non-Pharmacologic Interventions to Prevent SARS-CoV-2 Transmission, John W. Ward*, Coalition for Global Hepatitis Elimination, Task Force for Global Health
  • Korea's Public Health Responses to the COVID-19 Outbreak, Youngmee Jee, National Institute of Health (NIH), Korea
  • Impact of Health Disparities in the Treatment and Outcomes of Patients with COVID-19, Prof. John Carethers, University of Michigan School of Medicine

Note: Re-broadcast Saturday 9:00-10:30 pm

Sunday Nov 15th 3:30-4:30 pm ET | Covid-19 and the Clinical Liver Symposium Breakout Sessions

Monday, Nov 16th 10:30 am-12:00 pm | Parallel session: Hepatitis B: Non-Therapy

  • Do Novel Assays Improve Phenotypic Characterization of Adults with Chronic Hepatitis B?, Presenting Author Marc Ghany
  • End of Treatment HBsAg, HBCRAG and HBV RNA Levels Predict Risk of Off-Treatment ALT Flares in Patients with Chronic Hepatitis B, Presenting Author Sylvia Brakenhoff
  • Assocition of Asprin with Hepatocellular Carcinoma in Patients with Chronic Hepatitis B with or without Cirrhosis, Presenting Author Heejoon Jang
  • Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission in Mothers with High Viral Load: A Multicenter, Prosepctive, Observational Study, Presenting Author Qing-Lei Zeng
  • Rapid HBSAG Decline Instead of HBSAG Absolute Level Can Predict HBSAG Clearance in Community-Based Untreated Chronic Hepatitis B Cohort, Presenting Author Hsin-Che Lin
  • Country and WHO Regional Trends for Hepatitis B Virus (HBV) Mortality, 1990-2019: An analysis of the Global Burden of Disease (GBD) Study
    Presenting Author Rochelle Obiekwe *CGHE Author

Monday, Nov 16th | 12- 1:00 pm | A Conversation with the Newest Nobel Laureates with the 2020 recipients of the Nobel Prize in Physiology or Medicine, Drs. Harvey J. Alter, Michael Houghton, and Charles M. Rice

Monday, Nov 16th | 1-2:00 pm | Viral Hepatitis in the U.S. – The Road to Elimination

Moderators:

  • Michael Ninburg (Member, AASLD Patient Advisory Group)
  • Su Wang, MD, MPH (Member, AASLD Patient Advisory Group)

Presenter:

  • Carol Jimenez, JD (Deputy Director for Strategic Initiatives – Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, U.S. Department of Health & Human Services)

Panelists:

  • Jessica Deerin, MPH (Epidemiologist – Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, U.S. Department of Health & Human Services)
  • Judith Steinberg, MD, MPH (Chief Medical Officer – Office of Infectious Disease and HIV AIDS Policy, Office of the Assistant Secretary for Health, U.S. Department of Health and Human Services)
  • Carolyn Wester, MD, MPH (Director, Division of Viral Hepatitis, Centers for Disease Control and Prevention)

Posters:

 Re-treatment for HCV: Results from a preliminary retrospective analysis of pooled national program data across low- and middle-income countries, First Author: Christian Ramers *Coalition secondary authors

AASLD lists curated sessions for patients/advocates.

NVHR has also compiled a nice list of hepatitis and patient sessions.